Results for this period
Third quarter1 January 2026–30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
The shaded area represents net assets as a proportion of total assets. It is calculated from the two amounts reported by the company.
In Japan, performance benefited from sales price revisions reflecting higher raw material and labor costs, orders tracking above forecasts, increased sales volumes, profitability improvement initiatives, and adjustments to the timing of investment and repair plans. In China, the decline in pharmaceuticals for the US market, Chinese authorities' purchasing policy for low-priced pharmaceuticals, and lower orders from existing customers had an impact.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–30 September 2026 |
| Net Sales | ¥13,888 million (YoY +6.8%) |
| Operating profit | ¥510 million (YoY +60.6%) |
| Ordinary income | ¥507 million (YoY +42.0%) |
| Profit attributable to owners of the parent | ¥333 million (YoY +40.3%) |
| Total assets | ¥20,454 million |
| Net assets | ¥11,875 million |
| Segment revenue | Japan ¥12,180 million (YoY +8.3%), China ¥2,305 million (YoY -5.9%) |
| Segment profit | Japan ¥842 million (YoY +87.7%), China ¥-113 million |
| Depreciation and amortization | ¥448 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Factors Behind Changes in Business Performance | In Japan, performance benefited from sales price revisions reflecting higher raw material and labor costs, orders tracking above forecasts, increased sales volumes, profitability improvement initiatives, and adjustments to the timing of investment and repair plans. In China, the decline in pharmaceuticals for the US market, Chinese authorities' purchasing policy for low-priced pharmaceuticals, and lower orders from existing customers had an impact. |
Items this document does not state (23)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In Japan, sales price revisions reflecting higher raw material and labor costs, higher-than-expected orders, increased sales volumes, profitability improvement initiatives, and adjustments to the timing of investment and repair plans contributed to performance. In China, the decline in pharmaceuticals for the US market, Chinese authorities' purchasing policy for low-priced pharmaceuticals, and lower orders from existing customers had an impact.